Knowing how to put things into perspective before panicking
US POPULATION 327 200 000 – INFLUENZA DEATH TOLL = 0,0042% – 0,011%
CHINESE POPULATION 1 428 230 000 – COVID-2019 DEATH TOLL = 0,00012%
FLU INFLUENZA KILLING 100 TIMES MORE….BUT
On November 20, 2012, Novartis received FDA approval for the first cell-culture vaccine. In a 2007 report, the global capacity of approximately 826 million seasonal influenza vaccine doses (inactivated and live) was double the production of 413 million doses.
Without coverage, the retail price of the shot depends on your age and recommended vaccine formulation. At Walgreens, for instance, a shot that most adults and children would get runs $31.99 if you have no insurance. The price for the shot recommended for people age 65 and older is generally $59.99. Oct 30, 2017
413 000 000 X 31,99 U$ = 26 423 740 000 U$
FOR SUCH GOOD BUSINESS, ANYONE CAN TRAVEL THE WORLD FREELY AND SPREAD FLU
IN FRANCE ALONE FLUE CLAIMS AN AVERAGE OF 10 000 DEATHS PER YEAR
The medical controversies about the 2009 pandemic influenza vaccines concern the effects of the vaccine strain (risk of Guillain-Barré syndrome), adjuvants (the effects of squalene), the preservative (the effects of Thiomersal, containing mercury) or even production conditions (speed and still experimental nature of cell culture). All these subjects give rise, more particularly in France, to more or less divergent interpretations between the health authorities and various elements of civil society (part of the medical profession, unions, political leaders, etc.).
A note from November 19, 2009 from the WHO nonetheless concludes that “Although intense surveillance of vaccine safety is maintained, all the data processed to date indicates that the pandemic vaccine achieves the excellent level of vaccine safety. seasonal flu, which has been used for more than 60 years.32 “
Adjuvants to squalene
Critics [Who?] Of the vaccine suggest the following about squalene38:
They believe, from animal tests and childhood vaccination experience, that squalene promotes the development of autoimmune diseases.
They believe that squalene is implicated in Gulf War syndrome in veterans who have received multiple vaccines.
They believe that this product used massively to accelerate the production of vaccines has very little studied effects on health.
Advocates of the vaccine, like the WHO39 respond with the following points:
According to them, the link between squalene and autoimmune diseases has not been proven.
According to them, the Gulf War syndrome is not related to squalene.
More specifically, the three adjuvant formulas containing squalene used in the 2009 influenza A (H1N1) vaccines are:
The MF59C.1 from Novartis. This adjuvant has been present since 1997 in Novartis seasonal vaccines (Gripguard / Fluad). According to Le Figaro, in September 2009, “More than 40 million doses of this adjuvant based on squalene were administered worldwide, to risk groups or with immunosuppression, without any pharmacovigilance alert”, assures Dr. Martin (from WHO in Europe) 40. This adjuvant was however questioned by some in the context of the Gulf War syndrome, a causal link denied by several medical authorities.
GlaxoSmithKline AS03 (GSK). Opponents [Who?] Of the vaccine believe that “such an adjuvant has never been used before in a large-scale vaccine, and therefore may trigger excessive immune responses and increase the likelihood and frequency of rare side effects, but serious and dangerous. “According to Le Figaro in September 2009,” it has already been administered to 45,000 people “40.
AF03 from Sanofi-Aventis. It is the adjuvant of the Humenza vaccine, not yet authorized in Europe on November 16, 2009. This new adjuvant has been “tested only on a few thousand patients”, according to Le Figaro in September 200940.
Thiomersal is a mercury-based preservative additive for vaccines in multidose vials, used against the risk of microbial contamination. Invented in 1929, it was widely used in the medical world, until the taking into account of the risks linked to the presence of mercury led to advising its withdrawal (1999 in the United States, 2000 in France, but not everywhere worldwide and not systematically).
It is reintroduced for the purposes of mass vaccination in the vaccines presented in multidose ways against the pandemic influenza of 2009. The laboratories producing these vaccines respond to criticism by asserting that it is present in very low doses.